Company research
LIFECORE BIOMEDICAL, INC. \DE\
CIK 1005286Updated Sep 26, 2026
SecurityLFCR · NASDAQ · equity
Name history
LANDEC CORP \CA\ · through Nov 7, 2022
LFCR price & chart
Loading TradingView…
NASDAQ:LFCR on TradingView ↗About the company
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic
In the news
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS News provided by Halper Sadeh LLP Jan 29, 2026, 17:09 ET Share this article Share to X Share this article Share to X Shareholders should contact the firm immediately as there may be limited ↗
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS News provided by Halper Sadeh LLP Dec 24, 2025, 12:30 ET Share this article Share to X Share this article Share to X Shareholders should contact the firm immediately as there may be limited ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
SCHEDULE 13G filing
SCHEDULE 13D/A - filed by Legion Partners Asset Management, LLC regarding LIFECORE BIOMEDICAL, INC. \DE\
Regulation FD Disclosure
Items 7.01
Show 5 more recent filings
SCHEDULE 13D/A - filed by 22NW Fund, LP regarding LIFECORE BIOMEDICAL, INC. \DE\
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
4 filing
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 232,177,000Source | 253,960,000Source | 236,656,000Source | 277,806,000Source |
| Property, Plant and Equipment, NetUSD | 127,304,000Source | 148,598,000Source | 126,326,000Source | 118,531,000Source |
| GoodwillUSD | 13,881,000Source | 13,881,000Source | 13,881,000Source | 13,881,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 4,200,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 17,469,000Source | 8,462,000Source | 2,950,000Source | 1,643,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 31,153,000Source | 30,974,000Source | 48,172,000Source |
| Inventory, NetUSD | 29,085,000Source | 39,979,000Source | 42,042,000Source | 66,845,000Source |
| Assets, CurrentUSD | 82,292,000Source | 81,033,000Source | 83,126,000Source | 123,712,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,921,000Source | 1,439,000Source | 1,473,000Source | 7,052,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 2,442,000Source | 5,100,000Source | 8,580,000Source |
| Other Assets, NoncurrentUSD | 8,700,000Source | 3,806,000Source | 2,699,000Source | 3,002,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 198,117,000Source | 200,058,000Source | 163,100,000Source | 187,109,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 37,000Source | 30,000Source | 30,000Source | 30,000Source |
| Additional Paid in CapitalUSD | 208,962,000Source | 177,808,000Source | 174,243,000Source | 167,352,000Source |
| Retained Earnings (Accumulated Deficit)USD | -223,201,000Source | -166,523,000Source | -139,252,000Source | -76,099,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | -586,000Source |
| Stockholders' Equity Attributable to ParentUSD | -14,202,000Source | 11,315,000Source | 35,021,000Source | 90,697,000Source |
| Liabilities and EquityUSD | 232,177,000Source | 253,960,000Source | 236,656,000Source | 277,806,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 23,573,000Source | 38,872,000Source | 37,401,000Source | 176,810,000Source |
| Operating Lease, Liability, CurrentUSD | 372,000Source | 3,962,000Source | — | 1,743,000Source |
| Accounts Payable, CurrentUSD | 5,839,000Source | 16,334,000Source | 14,657,000Source | 15,802,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,120,000Source | 1,729,000Source | — | 9,971,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | 543,000Source | 80,000Source | 126,000Source |
| Other Liabilities, NoncurrentUSD | 6,698,000Source | 5,086,000Source | 203,000Source | 190,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 17,734,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 578,000Source | 543,000Source | — | 126,000Source |
| Long-term Debt, Current MaturitiesUSD | 954,000Source | 773,000Source | — | 98,178,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 100,819,000Source | 98,900,000Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -99,563,000Source | -114,679,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 8,027,000Source | 8,859,000Source | 13,285,000Source | 17,884,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,158,000Source | 6,201,000Source | 3,612,000Source | 2,608,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | -7,688,000Source | -862,000Source | 14,811,000Source | 5,960,000Source |
| Increase (Decrease) in Accounts PayableUSD | -1,670,000Source | -6,676,000Source | 16,038,000Source | 9,343,000Source |
| Deferred Income Tax Expense (Benefit)USD | -119,000Source | 156,000Source | 254,000Source | -6,324,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -206,000Source | -217,000Source | -17,441,000Source | -24,399,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -6,415,000Source | -17,921,000Source | -4,811,000Source | 81,768,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 13,415,000Source | — | — | 26,226,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 1,270,000Source | 152,000Source | 274,000Source | 789,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,424,000Source | 7,509,000Source | 39,700,000Source | -57,021,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | -1,365,000Source | — | — | — |
| Repayments of Long-term DebtUSD | — | 0Source | 123,690,000Source | 86,411,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -197,000Source | -10,629,000Source | 17,448,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 8,265,000Source | 8,462,000Source | 19,091,000Source | 1,643,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,907,000Source | 2,730,000Source | 31,024,000Source | 16,888,000Source |
| Income Taxes Paid, NetUSD | 46,000Source | 72,000Source | 23,000Source | 441,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,158,000Source | 6,201,000Source | 3,612,000Source | 2,608,000Source |
| Amortization of Intangible AssetsUSD | — | 0Source | 0Source | 1,382,000Source |
| Capitalized Computer Software, AmortizationUSD | — | 500,000Source | 500,000Source | 500,000Source |
| DepreciationUSD | 8,027,000Source | — | — | — |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | 0Source | -336,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | -7,776,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -18,000Source | -38,000Source | -152,000Source |
| Gain (Loss) on Termination of LeaseUSD | 2,642,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | -23,741,000Source | — |
| GoodwillUSD | 13,881,000Source | 13,881,000Source | 13,881,000Source | 13,881,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | 0Source | 1,300,000Source | 78,146,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 20,035,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | 14,150,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -38,717,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | 9,331,000Source | -64,236,000Source | -63,524,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | 2,682,000Source | -35,327,000Source | -51,155,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 0Source | — | — | — |
| Income Tax Expense (Benefit)USD | 43,000Source | 183,000Source | 308,000Source | -5,945,000Source |
| Inventory Write-downUSD | — | 800,000Source | 4,900,000Source | — |
| Investment Income, InterestUSD | 333,000Source | — | 68,000Source | 81,000Source |
| Net Income (Loss) Attributable to ParentUSD | -38,717,000Source | 12,013,000Source | -99,563,000Source | -114,679,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -44,359,000Source | — | — | — |
| Operating ExpensesUSD | — | 50,694,000Source | 49,781,000Source | 109,018,000Source |
| Other Nonoperating Income (Expense)USD | -3,000Source | -3,052,000Source | -1,159,000Source | 641,000Source |
| Proceeds from Issuance of Common StockUSD | 23,850,000Source | 0Source | 4,822,000Source | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | 150,000,000Source | 20,000,000Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 724,000Source | — | — |
| Financing Receivable, Credit Loss, Expense (Reversal)USD | — | 263,000Source | 163,000Source | — |
| Restructuring CostsUSD | — | — | 4,184,000Source | 8,961,000Source |
| Restructuring Costs and Asset Impairment ChargesUSD | — | 1,402,000Source | 640,000Source | 5,185,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 128,867,000Source | 128,261,000Source | 103,269,000Source | 185,786,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | 409,000Source | 39,500,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of RevenueUSD | 88,569,000Source | 86,411,000Source | 75,284,000Source | 135,416,000Source |
| Selling, General and Administrative ExpenseUSD | 44,046,000Source | 40,463,000Source | 38,969,000Source | 46,127,000Source |
| Operating Income (Loss)USD | -17,245,000Source | -8,844,000Source | -21,796,000Source | -58,648,000Source |
| Other Nonoperating Income (Expense)USD | -3,000Source | -3,052,000Source | -1,159,000Source | 641,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -38,674,000Source | 9,514,000Source | -63,928,000Source | -69,469,000Source |
| Income Tax Expense (Benefit)USD | 43,000Source | 183,000Source | 308,000Source | -5,945,000Source |
| Net Income (Loss) Attributable to ParentUSD | -38,717,000Source | 12,013,000Source | -99,563,000Source | -114,679,000Source |
| Earnings Per Share, BasicUSD per share | -1.27Source | 0.4Source | -3.32Source | -3.9Source |
| Earnings Per Share, DilutedUSD per share | -1.27Source | 0.32Source | -3.32Source | -3.9Source |
| Total Revenue | — | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 34,818,906Source | 30,474,000Source | 29,958,000Source | 29,466,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 34,818,906Source | 36,658,000Source | 29,958,000Source | 29,466,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | 0Source | 0Source | 1,382,000Source |
| Capitalized Computer Software, AmortizationUSD | — | 500,000Source | 500,000Source | 500,000Source |
| Cost, Depreciation and AmortizationUSD | — | — | — | 10,757,000Source |
| Current Income Tax Expense (Benefit)USD | 162,000Source | 27,000Source | 54,000Source | 379,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | 8,000,000Source | 10,300,000Source | 9,300,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 20,035,000Source |
| Gross ProfitUSD | 40,298,000Source | 41,850,000Source | 27,985,000Source | 50,370,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -38,717,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | 9,331,000Source | -64,236,000Source | -63,524,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -1.27Source | 0.31Source | -2.14Source | -2.16Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -1.27Source | 0.25Source | -2.14Source | -2.16Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | 2,682,000Source | -35,327,000Source | -51,155,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 0Source | — | — | — |
| Interest ExpenseUSD | — | — | 17,649,000Source | 17,357,000Source |
| Interest Expense, DebtUSD | 22,168,000Source | — | — | — |
| Investment Income, InterestUSD | 333,000Source | — | 68,000Source | 81,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -44,359,000Source | — | — | — |
| Operating ExpensesUSD | — | 50,694,000Source | 49,781,000Source | 109,018,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | 3,318,000Source | — | — | — |
| Research and Development ExpenseUSD | 8,258,000Source | 8,575,000Source | 8,736,000Source | 7,841,000Source |
| Restructuring CostsUSD | — | — | 4,184,000Source | 8,961,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 128,867,000Source | 128,261,000Source | 103,269,000Source | 185,786,000Source |
Filing attachments
ex992_lfcrpresentation.htm · 8-K · 2026-08-05
EX-99.2 3 ex992_lfcrpresentation.htm EX-99.2 ex992_lfcrpresentation Building a high-performing, growth-focused, sterile injectable CDMO August 2026 Exhibit 99.2 2 Important Information Regarding Forward-Looking Statements This presentation contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Secu…
Read attachment ↗ex992_lfcrpresentation.htm · 8-K · 2026-05-06
EX-99.2 3 ex992_lfcrpresentation.htm EX-99.2 ex992_lfcrpresentation Building a high-performing, growth-focused, sterile injectable CDMO May 2026 2 Important Information Regarding Forward-Looking Statements This presentation contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange …
Read attachment ↗ex992_lfcrpresentation.htm · 8-K · 2026-03-16
EX-99.2 3 ex992_lfcrpresentation.htm EX-99.2 ex992_lfcrpresentation Building a high-performing, growth-focused, sterile injectable CDMO March 2026 2 Fiscal Year Change On August 1, 2025, our Board of Directors approved a change in the Company’s fiscal year that ended on the last Sunday of May to a fiscal year that corresponds with the calendar year, ending on December 31st, effective for the fiscal period beginning May 26, 2025, and ending December 31, 2025 (the “Fiscal Year Change”). The …
Read attachment ↗ex992_lfcrpresentation.htm · 8-K · 2025-11-06
EX-99.2 3 ex992_lfcrpresentation.htm EX-99.2 ex992_lfcrpresentation November 2025 2 Important Information Regarding Forward-Looking Statements This presentation includes forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. These statements, among other things, relate to th…
Read attachment ↗ex991_lfcrpresentation.htm · 8-K · 2025-08-12
EX-99.1 2 ex991_lfcrpresentation.htm EX-99.1 ex991_lfcrpresentation August 2025 2 Important Information Regarding Forward-Looking Statements This presentation includes forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. These statements, among other things, relate to the …
Read attachment ↗a2025-01x17form8xkex991.htm · 8-K · 2025-01-17
EX-99.1 2 a2025-01x17form8xkex991.htm EX-99.1 Document Exhibit 99.1 Lifecore Biomedical Announces Special Stockholder Meeting Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms CHASKA, Minn., January 17, 2025 -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced…
Read attachment ↗